27 Sep 2013, BioSpectrum Bureau , BioSpectrum
Singapore: US-based Forest Laboratories and Forest laboratories Holding, along with Royalty Pharma has filed joint lawsuits in the Court for the infringement of the Savella related patents by several companies. Amongst the firms against whom the suits have been filed are leading Indian drugmakers, Lupin and Ranbaxy.
"The defendants named in the lawsuits include Apotex Corp, Hetero USA Inc, Lupin Ltd, Mylan Pharmaceuticals Inc, Par Pharmaceuticals Inc, Ranbaxy Laboratories Ltd, and related companies and subsidiaries," the company said in an official statement.
"Forest and Royalty Pharma received notification from these companies that they had filed Abbreviated New Drug Applications with Paragraph IV certifications seeking approval to market generic versions of Savella before the expiration of the ‘911 patent, the ‘342 patent, and the ‘220 patent," the statement explained.
Generic drug majors filed ANDA's to get 180 days of market exclusivity for the drug Savella that is used in the treatment of a chronic pain disorder called fibromyalgia.
Forest Laboratories has said that the lawsuits were commenced before the expiration of 45 days from the date of receipt of each notification letter.